Synairgen plc (LON:SNG – Get Free Report) shares rose 17.8% during mid-day trading on Thursday . The company traded as high as GBX 4.30 ($0.06) and last traded at GBX 4.30 ($0.06). Approximately 136,243 shares were traded during trading, a decline of 62% from the average daily volume of 354,848 shares. The stock had previously closed at GBX 3.65 ($0.05).
Synairgen Stock Up 17.8 %
The firm’s fifty day simple moving average is GBX 4.39 and its 200-day simple moving average is GBX 5.34. The company has a market cap of £8.66 million, a PE ratio of -107.50 and a beta of -2.23. The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09.
About Synairgen
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than Synairgen
- Consumer Staples Stocks, Explained
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- Market Cap Calculator: How to Calculate Market Cap
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Investing in the High PE Growth Stocks
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
